Presentation is loading. Please wait.

Presentation is loading. Please wait.

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer  Charles M.

Published byΦωτεινή Ελευθερίου Modified over 5 years ago

Similar presentations

Presentation on theme: "Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer  Charles M."— Presentation transcript:

1 Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer  Charles M. Rudin, MD, PhD, Kelvin Hong, MD, Michael Streit, MD  Journal of Thoracic Oncology  Volume 8, Issue 5, Pages e41-e42 (May 2013) DOI: /JTO.0b013e31828bb1b3 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Metastatic lung cancer response to dabrafenib. Serial computed tomography scans of the right lung are shown, pretreatment, at first ontreatment assessment (6 weeks) and after 4 months of therapy. Multiple pulmonary nodules and a malignant effusion are evident at baseline. The partial response at 6 weeks was confirmed on multiple subsequent scans, before disease progression as described. Journal of Thoracic Oncology 2013 8, e41-e42DOI: ( /JTO.0b013e31828bb1b3) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 MAPK signaling in nontransformed and cancer cells. Left: wild-type signaling. In most cells the MAPK pathway is tightly regulated by ligand-dependent activation of receptor tyrosine kinases, which signal through any of three RAS family GTPs (N-, K-, and H-RAS, depending on the cell type). RAS-GTP in turn triggers dimerization and activation of RAF family tyrosine kinases (A-, B-, and C-RAF), leading to activation of the downstream proliferative signaling pathway. Middle: oncogenic BRAF signaling. The BRAFV600E mutation promotes kinase activity as a monomer and is independent of RAS regulation, leading to potent and constitutive activation of the pathway. Such cells may be highly responsive to BRAF inhibitor therapy. Right: secondary KRAS mutation. A KRASG12D mutation locks KRAS in the GTP-bound (ON) configuration, independent of receptor tyrosine kinase regulation. Oncogenic KRAS activates multiple downstream pathways regulating proliferation and survival (not shown here). Among other effects, it may bypass inhibition of BRAFV600E by BRAF inhibitors, through stimulating dimerization of other RAF family members, leading to downstream activation of the MAPK pathway. BRAF, ; KRAS, ; MAPK, mitogen-activated protein kinase; GTP, . Journal of Thoracic Oncology 2013 8, e41-e42DOI: ( /JTO.0b013e31828bb1b3) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer  Charles M."

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Lung Cancer Tumour Markers

Lung Cancer Tumour Markers
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Inhibitor of MAP kinase activation blocks colon cancer growth

Inhibitor of MAP kinase activation blocks colon cancer growth
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification  Justin.
Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer  Roberto Ferrara, MD, Nathalie Auger, MD, Edouard Auclin,
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
Targeted Therapies in Melanoma: Translational Research at Its Finest

Targeted Therapies in Melanoma: Translational Research at Its Finest
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
On the TRAIL to Overcome BRAF-Inhibitor Resistance

On the TRAIL to Overcome BRAF-Inhibitor Resistance
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib

Similar presentations

Ads by Google